ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM

AZD1775 is an oral small molecular inhibitor of the G2/M checkpoint regulator Wee1. The Adult Brain Tumor Consortium 1202 trial (NCT01849146) is a phase I, open label, multicenter dose-finding study of AZD1775 in combination with standard RT and TMZ followed by an IDD study for patients undergoing s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Alexander, Brian, Supko, Jeffrey, Agar, Nathalie, Ahluwalia, Manmeet, Desai, Arati, Dietrich, Jorg, Kaley, Thomas, Peereboom, David, Takebe, Naoko, Desideri, Serena, Fisher, Joy, Sims, Megan, Ye, Xiaobu, Ligon, Keith, Nabors, L Burt, Grossman, Stuart, Wen, Patrick
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216169/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.048
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados